Abstract
The authors have reviewed some of the possible reasons for the lack of complete correlation between tumor estrogen-receptor analysis and response to endocrine therapy in the present article. While the analysis of progesterone receptors in breast cancer seems to have improved the ability to select patients for endocrine therapy, it is still not completely predictive. Other measures of estrogen responsiveness are currently under investigation. A wide variety of ablative and additive endocrine therapies have been used successfully in patients with breast cancer. In addition, numerous cytotoxic chemotherapy regimens have proved effective in the treatment of this disease. Whenever possible, tumor samples should be obtained for both estrogen- and progesterone-receptor analysis before any therapy is started. Once this information is obtained, the physician can then make a decision regarding therapy, which would have a high probability of success while minimizing the risk to the patient.
| Original language | English |
|---|---|
| Pages (from-to) | 363-366 |
| Number of pages | 4 |
| Journal | Archives of Internal Medicine |
| Volume | 142 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 1 1982 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Internal Medicine
Cite this
Steroid receptors in breast cancer. / Cowan, K.; Lippman, Marc E.
In: Archives of Internal Medicine, Vol. 142, No. 2, 01.01.1982, p. 363-366.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Steroid receptors in breast cancer
AU - Cowan, K.
AU - Lippman, Marc E
PY - 1982/1/1
Y1 - 1982/1/1
N2 - The authors have reviewed some of the possible reasons for the lack of complete correlation between tumor estrogen-receptor analysis and response to endocrine therapy in the present article. While the analysis of progesterone receptors in breast cancer seems to have improved the ability to select patients for endocrine therapy, it is still not completely predictive. Other measures of estrogen responsiveness are currently under investigation. A wide variety of ablative and additive endocrine therapies have been used successfully in patients with breast cancer. In addition, numerous cytotoxic chemotherapy regimens have proved effective in the treatment of this disease. Whenever possible, tumor samples should be obtained for both estrogen- and progesterone-receptor analysis before any therapy is started. Once this information is obtained, the physician can then make a decision regarding therapy, which would have a high probability of success while minimizing the risk to the patient.
AB - The authors have reviewed some of the possible reasons for the lack of complete correlation between tumor estrogen-receptor analysis and response to endocrine therapy in the present article. While the analysis of progesterone receptors in breast cancer seems to have improved the ability to select patients for endocrine therapy, it is still not completely predictive. Other measures of estrogen responsiveness are currently under investigation. A wide variety of ablative and additive endocrine therapies have been used successfully in patients with breast cancer. In addition, numerous cytotoxic chemotherapy regimens have proved effective in the treatment of this disease. Whenever possible, tumor samples should be obtained for both estrogen- and progesterone-receptor analysis before any therapy is started. Once this information is obtained, the physician can then make a decision regarding therapy, which would have a high probability of success while minimizing the risk to the patient.
UR - http://www.scopus.com/inward/record.url?scp=0020062047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020062047&partnerID=8YFLogxK
U2 - 10.1001/archinte.142.2.363
DO - 10.1001/archinte.142.2.363
M3 - Article
C2 - 7036926
AN - SCOPUS:0020062047
VL - 142
SP - 363
EP - 366
JO - JAMA Internal Medicine
JF - JAMA Internal Medicine
SN - 2168-6106
IS - 2
ER -